4/A: Palvella Therapeutics CEO Wes Kaupinen Acquires Stock Options
SEC Form 4/A
Wes Kaupinen, President and CEO of Palvella Therapeutics, acquired 243,831 non-qualified stock options on February 5, 2025.
Summary
- Wes Kaupinen, the President and CEO of Palvella Therapeutics, acquired 243,831 non-qualified stock options on February 5, 2025.
- The exercise price of these options is $14.76.
- The options vest in equal monthly tranches over 48 months and expire on February 5, 2035.
- This Form 4/A is an amendment to reflect a change in the reporting person's name from Palvella Therapeutics, Inc to Wes Kaupinen.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reports a standard executive compensation event. The CEO receiving stock options is generally viewed as a positive, but the document itself is simply a regulatory filing.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
- The vesting schedule of 48 months is a standard practice to incentivize long-term commitment.
- Comparing the size of this grant to similar companies and executive roles would provide further context on its significance.
Stakeholder Impact
- The stock option grant aligns the CEO's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of the stock option transaction. |
| 02/05/2035 | Expiration date of the stock options. |
| 02/10/2025 | Date of the Form 4/A filing. |
Keywords
stock options, Form 4, Palvella Therapeutics, Wes Kaupinen, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.